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Introduction
Innate immunity to pathogens uses pathogen-associated molecular patterns (PAMPs) to increase IL-1β and IL-18 release from inflammatory cells (Schroder & Tschopp, 2010) .
Lipopolysaccharide (LPS) is an example of a PAMP that can bind to Toll-Like Receptors
(TLR) to initiate innate immune responses (Takeuchi & Akira, 2010) . In addition, during sterile inflammation, danger-associated molecular patterns (DAMPs) can be released from dead cells to promote innate immune responses via TLR-dependent pathways (Chen & Nunez, 2010) . The NLRP (NOD-like receptor family, pyrin domain containing) inflammasome senses DAMPs, resulting in the binding of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) to the inflammasome. This, in turn, promotes assembly and activation of caspase-1, which cleaves pro-IL-1β to produce bioactive IL-1β which is then released from cells (Brough & Rothwell, 2007) . DAMPs might also be released from the damage to lysosomal membranes, which is regulated by lysosomal proteases, such as cathepsin B (Hornung & Latz, 2010) . Recently, Luheshi et al. (2012) demonstrated that sphingosine and the sphingosine analogue, FTY720, promote the NLRP3-dependent release of IL-1β from LPS-stimulated macrophages, as this was not evident in macrophages derived from Nlrp3 -/-mice. The effect of sphingosine on IL-1β release involves the protein phosphatase 2A and/or protein phosphatase 1 (PP2A/PP1). Thus, the PP2A/PP1 inhibitors okadaic acid and calyculin A prevented sphingosine-induced IL-1β release from macrophages (Luheshi et al. 2012) . Moreover, sphingosine-induced IL-1β release was unaffected by the cathepsin B inhibitor, CA074Me, or the pan-cysteine protease inhibitor, E64 (Luheshi et al. 2012) . The possibility that the effect of sphingosine on NLRP3-dependent release of IL-1β is mediated through metabolites of sphingosine was excluded based on the finding that ceramide, which is formed by acylation of sphingosine (catalysed by ceramidase and/or ceramide synthase) had no effect on IL-1β release. Moreover, much higher concentrations of sphingosine 1-phosphate (compared with sphingosine), which is produced by phosphorylation of sphingosine by the action of sphingosine kinase (two isoforms termed SK1 and SK2), were required in order to stimulate IL-1β release (Luheshi et al. 2012) . These findings can possibly be explained by evidence showing that sphingosine potently binds to the acidic leucine rich nuclear phosphoprotein-32A (ANP32A) to activate PP2A (Habrukowich et al. 2010) , and that this might also underlie the ability of sphingosine to inhibit cell growth and induce apoptosis of mammalian cells (Ohta et al. 1995; Nava et al. 2000) and to reduce tumour growth in vivo (Kohno et al. 2006 ).
Multiple sclerosis is an autoimmune inflammatory demyelinating disease involving reactive T-lymphocytes. There is also a strong prognostic relationship between IL-1β levels and disease progression and mutation of the Nlrp3 gene is associated with MS-like lesions (Compeyrot-Lacassagne et al. 2009; Dodé, et al. 2002) . In addition, mice lacking the gene encoding NLRP3 (Nlrp3 -/-) develop significantly milder symptoms in an experimental autoimmune encephalomyelitis (EAE) model and exhibit a reduction in IFNγ-and IL-17-expressing TH cells in peripheral lymphoid tissues and the spinal cord (Gris et al. 2010; Inoue et al. 2012) . IL-1β also induces activation of microglial cells, which stimulate Tlymphocytes with self-antigen during EAE development. In addition, IL-1 receptor deficient mice develop milder EAE and reduced TH17 cells (Sutton et al. 2006) . There is also a relationship between multiple sclerosis, NLRP3 inflammasome and the sphingosine analogue, FTY720. Indeed, FTY720 has been shown to activate PP2A, to stimulate IL-β release via an NLRP3-dependent mechanism in macrophages (Luheshi et al. 2012) and to modulate the immune response by preventing egress of T-lymphocytes from lymph nodes (Hla & Brinkmann, 2011) . FTY720 is licenced for oral treatment of relapsing multiple sclerosis under the trade name Gilenya TM . FTY720 is a prodrug, which is phosphorylated by SK2 and is a functional antagonist of sphingosine 1-phosphate receptor 1 (S1P 1 ), causing this receptor to be degraded by the proteasome and removed from T-lymphocytes (Hla & Brinkmann, 2011) . Since T-lymphocytes use an S1P gradient to egress from lymph nodes, FTY720 is able to prevent this by creating S1P 1 null T-lymphocytes that do not respond to the S1P gradient. This traps the T-lymphocytes in lymph nodes, thereby preventing their action on the CNS in multiple sclerosis.
In the current study, we have assessed whether ether glycerol lipids can affect inflammasome-dependent IL-1β release from macrophages and modify disease progression in the EAE model. The rationale for this was three-fold. First, there is structural similarity of the ether glycerol lipids with sphingosine and therefore these molecules might act in a similar manner as sphingosine to modulate inflammasome-dependent IL-1β release. Second, if modulation of inflammasome-dependent IL-1β release is evident, then these ether glycerol lipids might serve as a starting point for the synthesis of potent inhibitors of the inflammasome that can be used therapeutically to abrogate inflammatory diseases.
Alternatively, the synthesis of potent inflammasome activators could be used promote innate immunity against invading pathogens. Third, previous studies using 1-O-hexadecyl-2-desoxy-2-amino-sn-glycerol (which is 56-5) have demonstrated its phosphorylation by SK1
(K m = 3.8 µM, compared with K m = 15.7 µM for sphingosine (sphing-4-enine) (Gijsbers et al. 2002) . Indeed, we show here that ether glycerol lipids are substrates for SK1 and SK2, and that 77-6 is a powerful stimulator of IL-1β release from macrophages. However, 56-5 which fails to stimulate IL-1β release in U937 macrophage-like cells, increases disease progression in the EAE model. This action of 56-5 might be related to its chemical similarity with platelet activating factor, which also has a role in multiple sclerosis (Kihara et al. 2005) .
Results and Discussion
77-6 and 56-5 are substrates for both SK1 and SK2--We assessed whether several ether glycerol lipids (56-2, 56-3, 56-4, 56-5, 77-5 and 77-6; Fig. 1 ) and a sphingosine analogue (67- Fig. 1 ) inhibit SK1 and SK2 activity and/or function as substrates for these enzymes (Table 1 ). The replacement of the azide group in 56-4; a compound which inhibited SK2 activity, with an -NH 2 group produced compound 56-5 ((S)-2-Amino-3-O-hexadecyl-1-propanol or 1-O-hexadecyl-2-desoxy-2-amino-sn-glycerol), which was a substrate for SK2 (Table 1) . 56-5 was also a weak substrate for SK1, being ~ 5 times less effective than for SK2 (Table 1) . Similarly, replacement of the azide in 77-5 with an -NH 2 group produced compound 77-6 ((2S, 3R)-4-(Tetradecyloxy)-2-amino-1,3-butanediol), which was a substrate for SK2; this being ~ 3 times as effective compared with 56-5 (Table 1) . Therefore, reduction in the alkyl chain length from C16 to C14 and introduction of the 3-hydroxyl group, enhanced substrate utilization by SK2. Indeed, the 3-hydroxyl group of the naturally occurring substrate of SK2, sphingosine, might H-bond with D308 to orientate the 1-hydroxyl group for phosphorylation by the enzyme. 77-6 was also a preferred substrate for SK1 compared with 56-5. 56-5 and 77-6 bear chemical resemblance with sphingoid bases and this might therefore provide explanation for why these molecules can function as substrates for both SK1 and SK2. Indeed, the effect of carbon alkyl chain length on the efficiency of phosphorylation suggests an optimal fit in the catalytic site of both SK1 and SK2 in terms of the positioning the -OH group in the sphingosine binding pocket close to the deprotonating base to enable efficient phosphorylation. In contrast, the sphingosine analogue, 67-622 was a selective inhibitor of SK1 with no inhibitor activity against SK2 (Table 1) . 67-622 was not a substrate for SK1 or SK2 (Table 1) .
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Effect of 77-6 and 56-5 on IL-1β release--Others have shown that sphingosine stimulates IL-1β release from macrophages via activation of the NLRP3 inflammasome (Luheshi et al. 2012) . Therefore, given the chemical similarity with sphingosine, we investigated the effect of 56-5 and 77-6 on IL-1β release from macrophages. We show here that treatment of differentiated (macrophage-like) U937 cells with 77-6 (10 µM) increased basal and LPSstimulated IL-1β release in differentiated U937 cells ( Fig. 2A, B) . Similarly, treatment of differentiated U937 cells with sphingosine enhanced LPS-stimulated IL-1β release (Fig. 3 ).
In contrast, 56-5 (10 µM) was ineffective in stimulating IL-1β release from these cells; either alone or in the presence of LPS ( Fig. 2A, B) . Thus, the presence of the 3-OH group and/or C14 alkyl chain length (2 carbons shorter than in 56-5) in 77-6 is required to stimulate IL-1β
release from macrophages suggesting some structural-activity relationship with respect to the modulation of inflammasome activity.
In order to exclude the possibility that potential metabolites of sphingosine are responsible for its effects on IL-1β release, we tested S1P, which is formed by the action of sphingosine kinase on sphingosine. We also tested the effect of short chain ceramides. S1P and short chain ceramides and the SK2 selective inhibitor, (R)-FTY720 methylether (ROMe) (Lim et al. 2011b ) had no effect on LPS-stimulated IL-1β release (Fig. 4) . Similarly, the SK1/2 inhibitor, SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole) failed to modulate LPS-stimulated IL-1β release (data not shown). Taken together, these results suggest that the effect of 77-6 (Fig. 2 ) is not via modulation of the sphingolipid rheostat (e.g. inter-conversion of ceramide, sphingosine and S1P). Neither sphingosine, 56-5 nor 77-6 affected basal or LPS-stimulated TNFα release (data not shown), suggesting that the ability of 77-6 to increase IL-1β release is regulated by a distinct mechanism (e.g. inflammasome) from that regulating TNFα expression.
The effect of sphingosine or 77-6 on LPS-stimulated IL-1β release was reduced by pretreatment of cells with the caspase-1 inhibitor, Ac-YVAD-CHO ( where okadaic acid reduced the effect of sphingosine on IL-1β release and CA074Me had no effect. There is a major difference in the response of U937 macrophage like cells and primary macrophages, as in the latter case, LPS alone has no effect on IL-1β release (Luheshi et al. 2012 ), while in U937 macrophage like cells, LPS alone is able to stimulate IL-1β release.
These findings suggest that the mechanisms of LPS-stimulated IL-1β release are somewhat different in the two cell systems. Therefore, it is reasonable to conclude that the DAMPmediated effect of sphingosine could also involve different mechanisms of inflammasome modulation in the two cellular systems. For instance, different family members of NLRP inflammasome might be involved in the two cell types. The effect of sphingosine, but not 77-6, on LPS stimulation of IL-1β release was also reduced by the cyclic AMP elevating agent, forskolin ( Fig. 8) , thereby indicating along with the differential effect of cathepsin B inhibitor, that sphingosine and 77-6 use different mechanisms involving the inflammasome to potentiate LPS-stimulated IL-1β release from macrophages.
Effect of 56-5 and 77-6 on disease progression in EAE--Since the inflammasome is linked
with multiple sclerosis, we tested the effect of 56-5 and 77-6 on disease progression in EAE, an animal model of multiple sclerosis. In this regard, 56-5 increased disease progression (clinical score) with an earlier onset of symptoms that were more severe ( Fig. 9A ) in the EAE model and induced a considerable increase in infiltration in CD4 + T-cells, CD11b + monocytes and F4/80 + macrophages in the spinal cord (Fig, 9B ). In contrast, 77-6 was without effect on disease progression (Fig. 9A B) . FTY720, used as a positive control, completely ablated disease progression (clinical score) in the EAE model (Fig. 9A ). These findings demonstrate the opposite structural-activity relationship when compared to the modulation of IL-1β release and suggest that the targets for 77-6 and 56-5 are different in the two experimental systems.
The amino ether lipid 56-5 is an intermediate in the chemical synthesis of an amide analogue of PAF (1-O-alkyl-2-acetyl-sn-glycerol-3-phosphocholine) (Chandrakumar & Hadju, 1982) and bears some chemical similarity to PAF, which is also involved in disease progression in EAE. Indeed, PAF levels and PAF receptor mRNA expression in the spinal cord are correlated with the EAE disease progression. Moreover, PAF receptor knockout mice exhibit a lower incidence and less severe symptoms in the chronic phase of EAE compared with WT mice (Kihara et al. 2005 ). In addition, macrophages from PAF receptor knockout mice exhibit enhanced phagocytic activity and TNF-α production. Therefore, the ability of 56-5 to enhance disease progression in the EAE model might be related to its potential activity in modulating PAF receptor signaling. This possibility will be tested by further experimentation in the future.
Effect of FTY720, 56-5 and 77-6 on S1P 1 receptor internalization--Since FTY720, when converted by SK2 to FTY720-phosphate, is a functional antagonist of the S1P 1 receptor and this underlies a major part of its action in alleviating MS disease progression, we assessed the effect of 56-5 and 77-6 (both SK2 substrates) on S1P 1 receptor degradation in CCL39 cells (an expression system for analyzing S1P 1 receptor modifying agents) that were engineered to stably over-express S1P 1 . Unlike FTY720, which significantly reduced EAE severity and S1P 1 levels in CCL39 cells, 56-5 and 77-6 were without effect on the degradation of this receptor ( Fig. 10) , and also failed to stabilize the receptor as neither 56-5 nor 77-6 stimulated increased expression of S1P 1 . Therefore, it is unlikely that the effects of 56-5 on EAE progression involve modulation of the S1P 1 receptor or T-lymphocyte trafficking from lymph nodes via this mechanism (although this would need to be tested in T-cells themselves), despite increasing CD4 + infiltration into the spinal cord.
Conclusion
The ability of 56-5 to increase disease progression in the EAE model is not likely to be linked with the inflammasome based on the finding that 56-5 failed to increase IL-1β release from differentiated U937 cells; either alone or in the presence of LPS. Moreover, a significant role for inflammasome in the action of 77-6 is unlikely as although this compound does stimulate IL-1β release from macrophages, it had no significant effect on disease progression in the EAE model. Therefore, we have demonstrated a structural activity relationship in terms of regulation of the inflammasome and EAE disease progression by ether glycerol lipids, albeit that these relationships are opposed. 
Materials and Methods

HEK 293, U937 and CCL39 Cell Culture--HEK 293 cells stably over-expressing GFP-SK1
(30-fold increase in SK1 activity vs. vector-transfected cells) were cultured in DMEM supplemented with 10% European fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin, 1% non-essential amino acids, and 0.8% geneticin at 37 °C in 5% CO 2 . U937 cells (ATCC) were maintained in RPMI medium (Life Technologies), supplemented with 10% (v/v) foetal bovine serum (Seralabs), 1U /ml penicillin, 1 mg/ml streptomycin and 2 mM L-glutamine (Life Technologies; complete RPMI). U937 cells were differentiated using PMA as previously described by others (Shepherd et al. 2004; Twomey et al. 1993) . Briefly, cells were plated at 1 × 10 6 cells/ml in complete RPMI supplemented with 4nM PMA. Medium was replenished after two days. After 4 days, the cells were then cultured in complete RPMI in the absence of PMA for a further 24 hours. U937 cells were stimulated with 1 µg/ml LPS (Sigma) for 2 hours, after which compounds at indicated concentrations were added for 1 hour. Supernatants were collected and assayed for IL-1 protein expression by ELISA according to the manufacturer's instructions (R&D Systems). CCL39 cells that were stably transfected with myc-tagged S1P 1 (Rutherford et al., 2013) were maintained in DMEM with GlutaMAX TM supplemented with 10% (v/v) foetal bovine serum, 100 units/ml penicillin and 100 g/ml streptomycin at 37 °C in a humidified atmosphere containing 5% (v/v) CO 2 . Cells grown to confluence on 12 well plates were quiesced for 24 hours prior to treatment with FTY720 (100 nM) or 77-6 (10 µM) or 56-5 (10 µM) for 24 hours. Cell lysates were analysed by SDS-PAGE and western blotted for myc-tagged S1P 1 (# sc-40, Santa Cruz) and re-probed were incubated with secondary antibody (Sigma; diluted in blocking buffer) for 1 hour at room temperature. Immunoreactive protein bands were visualized using ECL.
Sphingosine Kinase Activity Assays--To assess the compounds as potential inhibitors of SK1 and SK2, enzyme activity was assayed at the K m values for sphingosine (SK1, 3 µM; SK2, 10 µM). This corresponds to 50% substrate saturation, thereby enabling a qualitative estimation of selectivity by comparing the % modulation of each kinase using a fixed concentration of compound (50 µM). In order to measure SK2 activity, Sph was complexed with fatty acid free bovine serum albumin (final concentration, 0.2 mg/mL) in buffer A containing 20 mM Tris (pH 7.4), 1 mM EDTA, 1 mM Na 3 VO 4 , 40 mM β-glycerophosphate, 1 mM NaF, 0.007% (v/v) β-mercaptoethanol, 20% (v/v) glycerol, 10 g/ml aprotinin, 10 g/mL soybean trypsin inhibitor, 1 mM PMSF, 0.5 mM 4-deoxypyridoxine, and 400 mM KCl. SK2 assays were performed using 37 ng of purified SK2 and incubating the assay for 30 min at 30 °C in the presence of 10 µM substrates of SK1 and SK2, the assay was conducted in the presence of 50 µM of the test compound (but in the absence of Sph) and radioactivity in the 1-butanol phase was quantified.
Mice--C57BL/6 mice were purchased from Harlan (UK) and maintained at the Biological Procedure Unit, University of Strathclyde. All experiments were performed under the guidelines of the UK Home Office Animals (Scientific Procedures) Act 1986. Female mice at the age of 7-12 weeks were used in all experiments. as before (Jiang et al., 2012) . Each mouse also received intraperitoneally (i.p.) 100 ng/200 µl of PTX (Sigma, UK) in PBS on days 0 and 2 post immunization. EAE was scored according to a 0 -5 scale as follows: 0, no clinical sign; 1, complete loss of tail tone; 2, hind limb weakness; 3, hind limb paralysis; 4, forelimb involvement; 5, moribund.
EAE Induction and Clinical Evaluation--Mice
Preparation of Compounds, Dosage and Route of Administration--All compounds were
dissolved in a vehicle solution of 20% cyclodextrin in phosphate buffered saline. FTY720
(Cambridge Bioscience, UK) was prepared as 0.05 mg/ml stock. The dosage given to the mice was 0.4 mg/kg. Compound 56-5 was prepared as 0.25 mg/ml stock. The dosage given was 2 mg/kg (the approximate in vivo concentration is 6.3 µM assuming 100% bioavailability).
Compound 77-6 was prepared as 1.0 mg/ml stock. The dosage given was 8 mg/kg (the approximate in vivo concentration is 25 µM assuming 100% bioavailability). The compounds were all administered i.p. daily from day 0 of MOG immunization at the above doses. The EAE control group received i.p. injection daily of the 20% cyclodextrin vehicle.
Immunohistochemical Staining--Mice were euthanized in CO 2 chamber and their spinal cords were flushed out with PBS by hydrostatic pressure using a syringe. Tissues were immediately frozen in OCT and 6-8µm thick sections were stained with specific primary antibodies for 1, 22.7, 26.1, 29.3, 29.4, 29.6, 29.6, 29.6, 29.7, 31.9, 64.2, 70.5, 71.8, 72 .5.
(S)-3-Hexadecyloxy-2-methoxy-1-propylamine (56-3) (Tsuri et al. 1992 ). 1-O-Hexadecyl-2-
O-methyl-sn-glycerol was synthesized by O-methylation of 1-O-hexadecyl-3-O-(4-
methoxyphenyl)-sn-glycerol as described previously (Byun et al. 1994 ). The azido group was introduced into the sn-3 position of 1-O-hexadecyl-2-O-methyl-sn-glycerol by using tosyl chloride followed by sodium azide as described previously. The azide group was reduced by hydrogenation of 56-2 (54 mg, 0.15 mmol) with Pd/C (5 mg) in methanol (20 mL), with stirring overnight. After Pd/C was removed by passing the mixture through a pad of Celite, the filtrate was concentrated under reduced pressure to give 50 mg of the target amino alcohol, 56-
(S)-2-Azido-3-O-hexadecyl-1,3-propanediol (56-4)
Regioselective azidotrimethylsilylation (Ponpipom & Bugianesi, 1984; He et al. 1999 ) of 3-O-hexadecyl-sn-glycerol was carried out as described previously (He et al. 1999; Byun et al. 2010 ) The activation of 3-O-hexadecyl-snglycerol (3.17 g, 10.0 mmol) with Ph 3 P (3.42 g, 13.0 mmol) and diisopropyl azodicarboxylate (DIAD, 3.2 mL, 15 mmol) followed by reaction with trimethylsilyl azide (TMSN 3 , 2.2 mL, 13 mmol) afforded crude the silyloxy azide, which was used without further purification. After removal silyl protecting group with tetra-n-butylammonium fluoride (TBAF, 25 mL of a 1 M solution in THF containing 5% H 2 O) the crude product was purified by silica gel (dt, 2H, J = 6.6, 1.5 Hz), 3.58-3.75 (m, 5H); 13 C NMR δ 14. 10, 22.68, 25.97, 29.35, 29.41, 29.56, 29.59, 29.65, 29.68, 31.91, 62.18, 63.09, 71.01, 71 .91.
(S)-2-Amino-3-O-hexadecyl-1,3-propanediol (56-5) (Gijsbers et al. 2002) . 1, 22.7, 26.1, 29.3, 29.44, 29.49, 29.56, 29.59, 29.6, 29.6, 31.9, 54.3, 64.4, 71.8, 72.0, 72.5 . 1, 22.7, 25.9, 29.3, 29.44, 29.48, 29.54, 29.63, 29.65, 29.67, 31.8, 31.9, 61.8, 70.6, 88.7, 123.9, 128.6, 134.9, 163.7, 166.9 1, 22.7, 26.1, 28.1, 29.4, 29.57, 29.62, 29.66, 29.7, 31.9, 32.8, 59.9, 70.2, 83.0, 88.9, 158.9 The free amine was found to be unstable. Figure 3 . Sphingosine enhances IL-1 release in the presence of LPS in differentiated U937 cells. Differentiated U937 cells were stimulated with LPS (1 µg/ml) for 2 hours prior to treatment with sphingosine (Sph, 20 µM) for 1 hour. The supernatants were collected and assayed for IL-1 by ELISA. Data shown are the mean ± SEM of at least 3 experiments. Student's T-test was carried out. ***p<0.001. Figure 4 . S1P, C2 ceramide and ROMe do not affect IL-1 release. Differentiated U937 cells were stimulated with LPS (1 µg/ml) for 2 hours prior to treatment with erythroS1P (1 and 10 µM), C2 ceramide (10 and 50 µM) or ROMe (10 µM) for 1 hour. The supernatants were collected and assayed for IL-1 by ELISA. Data shown are the mean ± SEM of at least 3 experiments. Student's T-test was carried out. ***p<0.001. Figure 5 . The Caspase-1 inhibitor Ac-YVAD-CHO prevents the enhancement of LPS-stimulated IL-1 release by 77-6 and sphingosine. Differentiated U937 cells were treated with vehicle (grey bars) or Ac-YVAD-CHO (10 µM) for 15 min (black bars), stimulated with LPS (1 µg/ml) for 2 hours prior to treatment with 56-5 or 77-6 (both at 10 µM) or 20 µM Sph for 1 hour. Data shown are the mean ± SEM of at least 3 experiments. Student's T-test was carried out. *p<0.05, **p<0.01, ns not significant. Figure 6 . The Cathepsin B inhibitor CA-074Me prevents the enhancement of LPS-stimulated IL-1 release by sphingosine but not 77-6. Differentiated U937 cells were treated with vehicle (grey bars) or CA-074Me (10 µM, black bars) for 15 min, stimulated with LPS (1 µg/ml) for 2 hours prior to treatment with 56-5 or 77-6 (both at 10 µM) or Sph (20 µM) for 1 hour. Data shown are the mean ± SEM of at least 3 experiments. Student's Ttest was carried out. *p<0.05, **p<0.01, ns not significant. Figure 7 . PP2A inhibitor okadaic acid does not affect IL-1 release. Differentiated U937 cells were stimulated with LPS (1 µg/ml) for 2 hours, treated with vehicle (grey bars) or okadaic acid (0.5 µM) for 15 min (black bars), prior to treatment with 56-5 or 77-6 (both at 10 µM) or 20 µM Sph for 1 hour. Data shown are the mean ± SEM of at least 3 experiments. Student's T-test was carried out. *p<0.05, **p<0.01, ***p<0.001, ns not significant. Figure 8 . Forskolin inhibits the enhancement of LPS-stimulated IL-1 release by sphingosine but not 77-6. Differentiated U937 cells were treated with vehicle (grey bars) or Forskolin (10 µM) for 30 min (black bars), stimulated with LPS (1 µg/ml) for 2 hours prior to treatment with 56-5 or 77-6 (both at 10 µM) or 20 µM Sph for 1 hour. Data shown are the mean ± SEM of at least 3 experiments. Student's T-test was carried out. *p<0.05, **p<0.01, ns not significant. Figure 10 . The effect 56-5, 77-6 or FTY720 on myc-tagged S1P 1 expression in CCL39 cells. CCL39 cells stably over-expressing myc-tagged S1P 1 were treated with 56.5 (10 µM) or 77-6 (10 µM) or FTY720 (100 nM) for 24 h. Cell lysates were then western blotted with anti-myc antibodies. Results are representative of 3 independent experiments.
Ethyl (2S,3R)-2-(O-
ABBREVIATIONS
DAMPs, Danger associated molecular patterns; DMEM, Dulbeccos Modified Eagles Medium; Table 1 SK1 and SK2 activity was measured according to the Methods. Compounds were tested in combination with sphingosine (control activity in assay with sphingosine alone =100%) or in the absence of sphingosine (activity in absence of compounds = 0%). 
